SI3237416T1 - Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba - Google Patents

Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba

Info

Publication number
SI3237416T1
SI3237416T1 SI201530743T SI201530743T SI3237416T1 SI 3237416 T1 SI3237416 T1 SI 3237416T1 SI 201530743 T SI201530743 T SI 201530743T SI 201530743 T SI201530743 T SI 201530743T SI 3237416 T1 SI3237416 T1 SI 3237416T1
Authority
SI
Slovenia
Prior art keywords
polycyclic
pharmaceutical use
carbamoylpyridone compounds
carbamoylpyridone
compounds
Prior art date
Application number
SI201530743T
Other languages
English (en)
Inventor
Elizabeth M. Bacon
Zhenhong R. Cai
Jeromy J. Cottell
Mingzhe Ji
Haolun Jin
Scott E. Lazerwith
Philip Anthony Morganelli
Hyung-Jung Pyun
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI3237416T1 publication Critical patent/SI3237416T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201530743T 2014-12-23 2015-12-21 Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba SI3237416T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096291P 2014-12-23 2014-12-23
EP15825729.5A EP3237416B1 (en) 2014-12-23 2015-12-21 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PCT/US2015/067155 WO2016106237A1 (en) 2014-12-23 2015-12-21 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Publications (1)

Publication Number Publication Date
SI3237416T1 true SI3237416T1 (sl) 2019-06-28

Family

ID=55168426

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530743T SI3237416T1 (sl) 2014-12-23 2015-12-21 Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba

Country Status (24)

Country Link
US (4) US9522912B2 (sl)
EP (2) EP3237416B1 (sl)
JP (3) JP6393835B2 (sl)
KR (4) KR101978167B1 (sl)
CN (2) CN111454273A (sl)
AR (1) AR103251A1 (sl)
AU (3) AU2015369817B2 (sl)
BR (1) BR102015032109A2 (sl)
CA (1) CA2969244C (sl)
EA (1) EA201791019A1 (sl)
ES (1) ES2732482T3 (sl)
HK (1) HK1244000B (sl)
IL (1) IL252532A0 (sl)
MA (1) MA45613A (sl)
MX (1) MX2017007814A (sl)
NZ (1) NZ732391A (sl)
PL (1) PL3237416T3 (sl)
PT (1) PT3237416T (sl)
SG (1) SG11201704421QA (sl)
SI (1) SI3237416T1 (sl)
TR (1) TR201909152T4 (sl)
TW (2) TWI738321B (sl)
UY (1) UY36465A (sl)
WO (1) WO2016106237A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164352A (en) 2012-12-21 2017-12-15 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
HUE056470T2 (hu) 2014-12-26 2022-02-28 Univ Emory Vírusellenes N4-Hidroxicitidin származékok
CN107531727B (zh) * 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN112218851A (zh) * 2017-11-02 2021-01-12 卡里科生命科学有限责任公司 整合应激通路的调节剂
US11939320B2 (en) 2017-11-02 2024-03-26 Abbvie Inc. Modulators of the integrated stress pathway
GB2590198B (en) 2017-12-07 2022-02-23 Univ Emory N4-hydroxycytidine derivatives and anti-viral uses related thereto
WO2019113419A1 (en) * 2017-12-08 2019-06-13 The Rockefeller University Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation
PE20201414A1 (es) 2018-05-31 2020-12-07 Shionogi & Co Derivado policiclico de piridona
MX2020012176A (es) 2018-05-31 2021-01-29 Shionogi & Co Derivado policiclico de carbamoilpiridona.
MX2021011394A (es) 2019-03-22 2021-10-13 Gilead Sciences Inc Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
WO2021093846A1 (zh) * 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 新型四环杂环化合物及其药物用途
JPWO2021107065A1 (sl) * 2019-11-28 2021-06-03
US20230059640A1 (en) * 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
CN114736173B (zh) * 2022-05-24 2024-06-11 无锡捷化医药科技有限公司 一种3-(二氟甲基)氧杂环丁烷-3-胺盐酸盐的制备方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
CA2353961A1 (en) 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Heteroaromatic derivatives having an inhibitory activity against hiv integrase
EP1297834A4 (en) 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
EP2266958B1 (en) 2001-08-10 2017-03-15 Shionogi & Co., Ltd. Antiviral agent
CZ2004442A3 (cs) 2001-10-03 2005-03-16 Ucb, S.A. Pyrrolidinonové deriváty
ME00427B (me) 2001-10-26 2011-10-10 Msd Italia Srl N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
ATE443048T1 (de) 2002-11-20 2009-10-15 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
MXPA05005448A (es) * 2002-11-26 2005-08-26 Ambient Corp Arreglo de un acoplador inductivo para comunicacion de linea de alimentacion.
US20060246130A1 (en) 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
JP2007519735A (ja) 2004-01-30 2007-07-19 メルク エンド カムパニー インコーポレーテッド Hivインテグラーゼ阻害剤として有用であるn−ベンジル−3,4−ジヒドロキシピリジン−2−カルボキサミド及びn−ベンジル−2,3−ジヒドロキシピリジン−4−カルボキサミド化合物
CN101014574A (zh) 2004-03-09 2007-08-08 默克公司 Hiv整合酶抑制剂
WO2005110414A2 (en) 2004-05-07 2005-11-24 Merck & Co., Inc. Hiv integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005112930A1 (en) 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
DE602005027466D1 (de) 2004-07-27 2011-05-26 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
SI3045206T1 (sl) 2005-04-28 2018-07-31 Viiv Healthcare Company Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo
US20060249072A1 (en) * 2005-05-05 2006-11-09 Csillag Frank J Method of synthesizing a fluoride growth material for improved outgassing
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
WO2007014352A2 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
CA2847871C (en) 2005-12-30 2016-07-26 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP2452682A1 (en) 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
NZ570706A (en) 2006-03-06 2010-08-27 Japan Tobacco Inc Methods for producing an 4-oxoquinoline compound
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. 4-オキソキノリン化合物の製造方法
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2009000661A (es) 2006-07-19 2009-03-27 Univ Georgia Res Found Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion.
ES2536923T3 (es) 2006-09-12 2015-05-29 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa del VIH
CA2665538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
AU2008218186C1 (en) 2007-02-23 2014-07-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
AR067184A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
BRPI0813000A2 (pt) 2007-06-29 2014-12-23 Gilead Sciences Inc Composições terapêuticas e uso das mesmas
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100272811A1 (en) 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320908B9 (en) 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
ES2449752T3 (es) 2008-07-25 2014-03-21 Viiv Healthcare Company Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida
PT2660239T (pt) * 2008-07-25 2017-02-24 Shionogi & Co Compostos químicos como intermediários sintéticos
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
CN102245182B (zh) 2008-12-11 2014-07-23 盐野义制药株式会社 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
JP2012512246A (ja) * 2008-12-17 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング C環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
EP2540720B1 (en) 2010-02-26 2015-04-15 Japan Tobacco, Inc. 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
PT2588450T (pt) 2010-07-02 2017-08-03 Gilead Sciences Inc Derivados do ácido naft-2-ilacético para tratamento da sida
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
HUE054473T2 (hu) 2010-08-05 2021-09-28 Shionogi & Co Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására
MX2013003139A (es) 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.
EP2699558B1 (en) 2011-04-21 2016-11-23 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9206197B2 (en) 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
CN103974957A (zh) 2011-10-12 2014-08-06 盐野义制药株式会社 具有整合酶抑制活性的多环吡啶酮衍生物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
WO2013103738A1 (en) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013159064A1 (en) 2012-04-20 2013-10-24 Gilead Sciences, Inc. Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
WO2014022707A1 (en) 2012-08-03 2014-02-06 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CA2893959A1 (en) 2012-12-14 2014-06-19 Shenshen Cai Pharmaceutical compositions
EP2931730B1 (en) * 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
MY164352A (en) * 2012-12-21 2017-12-15 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2014100077A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Gastro-retentive formulations
MX2015008467A (es) 2012-12-27 2015-09-23 Japan Tobacco Inc Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana.
EP2986291B1 (en) * 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
SG11201602217XA (en) 2013-09-27 2016-04-28 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN107531727B (zh) * 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途

Also Published As

Publication number Publication date
AU2020286299B2 (en) 2022-07-14
US20160176870A1 (en) 2016-06-23
IL252532A0 (en) 2017-07-31
HK1244000B (zh) 2020-05-22
AU2015369817B2 (en) 2018-10-25
MX2017007814A (es) 2017-09-18
KR102020004B1 (ko) 2019-09-06
CN107108643B (zh) 2020-06-05
AU2015369817A1 (en) 2017-06-22
JP2017538713A (ja) 2017-12-28
JP6934846B2 (ja) 2021-09-15
UY36465A (es) 2016-07-29
MA45613A (fr) 2021-04-28
WO2016106237A1 (en) 2016-06-30
US10646486B2 (en) 2020-05-12
US20210015816A1 (en) 2021-01-21
CA2969244C (en) 2020-05-05
PT3237416T (pt) 2019-07-23
KR102240584B1 (ko) 2021-04-15
EP3388431A1 (en) 2018-10-17
US20180110776A1 (en) 2018-04-26
JP6393835B2 (ja) 2018-09-19
AU2019200422B2 (en) 2020-09-10
AU2020286299A1 (en) 2021-01-21
PL3237416T3 (pl) 2019-09-30
TW201636347A (zh) 2016-10-16
JP2018172437A (ja) 2018-11-08
KR101978167B1 (ko) 2019-05-14
BR102015032109A2 (pt) 2016-07-05
AU2019200422A1 (en) 2019-02-07
CN107108643A (zh) 2017-08-29
EP3237416B1 (en) 2019-05-01
TW202106688A (zh) 2021-02-16
SG11201704421QA (en) 2017-07-28
ES2732482T3 (es) 2019-11-22
US9795602B2 (en) 2017-10-24
CN111454273A (zh) 2020-07-28
TR201909152T4 (tr) 2019-07-22
NZ732391A (en) 2018-12-21
EA201791019A1 (ru) 2017-12-29
TWI738321B (zh) 2021-09-01
KR20170097168A (ko) 2017-08-25
KR20190104458A (ko) 2019-09-09
US9522912B2 (en) 2016-12-20
US20170119764A1 (en) 2017-05-04
KR20190052172A (ko) 2019-05-15
CA2969244A1 (en) 2016-06-30
AR103251A1 (es) 2017-04-26
TWI695003B (zh) 2020-06-01
JP2020073560A (ja) 2020-05-14
KR20210042185A (ko) 2021-04-16
EP3237416A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
HK1243073A1 (zh) 治療性化合物及其用途
GB201403093D0 (en) Therapeutic compounds and their use
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
HK1232211A1 (zh) 二甲基吡啶胺衍生物及其醫藥用途
ZA201701492B (en) Pyrazolothiazole compound and medicine
GB201702464D0 (en) Pharmaceutical agent
GB201406115D0 (en) New pharmaceutical use
GB201517133D0 (en) New pharmaceutical use
GB201409662D0 (en) New pharmaceutical use
GB201616767D0 (en) New pharmaceutical use
GB201517454D0 (en) New pharmaceutical use
GB201517132D0 (en) New pharmaceutical use
GB201508611D0 (en) New pharmaceutical use
GB201508613D0 (en) New pharmaceutical use
GB201507813D0 (en) New pharmaceutical use
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201413411D0 (en) Novel compounds and their use